Request a Rep Icon

Busy Financial Advisor Who Adjusts His Daily Life Around Symptoms of UC

Meet Stephen
Meet Stephen

Meet StephenNot an actual patient.


Stephen’s Background
  • Male, age 36; married with 2 young children
  • Wakes up early to use the bathroom before his commute and always packs a spare set of clothes for work travel
Stephen’s Medical History
  • Left-sided moderately active UC
  • Mayo endoscopy subscore=2
  • Abdominal pain and cramping, with about 6 loose stools per day and presence of blood
  • Currently on 5-ASAs; 1 tapering course of steroids (in the past year)
  • No history of cardiac or ophthalmic issues
Treatment Plan Considerations
  • Prefers oral therapy
  • Doesn’t have the time to spend in an infusion clinic between work and family commitments
At TRUE NORTH Study Baseline (N=645)1a:
  • 86% of patients had moderate disease (Mayo score 6–10)1
  • ~66% of patients were advanced therapy-naïve2
  • 33% of patients were taking concomitant oral steroids1
  • aClinical Trial: the efficacy and safety of ZEPOSIA were evaluated in 2 multicenter, randomized, double-blind, placebo-controlled clinical studies (UC Study 1 [induction] and UC Study 2 [maintenance]) in adult patients with moderately to severely active UC, defined as a Mayo score of 6 to 12 at baseline.1

  • Primary Endpoint of Clinical Remission Is Defined as: RBS=0, SFS=0 or 1 (and a decrease of ≥1 point from baseline SFS), and endoscopy subscore=0 or 1 without friability. At Week 10, 18% of patients taking ZEPOSIA achieved clinical remission vs 6% of patients taking placebo (p<0.0001). At Week 52, 37% of patients taking ZEPOSIA achieved clinical remission vs 19% of patients taking placebo (p<0.0001).1

  • Secondary Endpoint of Clinical Response Is Defined as: a reduction from baseline in the 3-component Mayo score of ≥2 and ≥35%, and a reduction from baseline in the RBS of ≥1 or an absolute RBS of 0 or 1.1

  • UC Study 1 (10-Week Induction): 645 patients were randomized 2:1 to either ZEPOSIA 0.92 mg given orally once daily or placebo for 10 weeks, beginning with a dosage titration. The trial included patients who had an inadequate response or were intolerant to any of the following: oral aminosalicylates, corticosteroids, immunomodulators, or a biologic. Patients were required to be on stable doses of oral aminosalicylates and/or corticosteroids.1

  • UC Study 2 (42-Week Maintenance): 457 patients who received ZEPOSIA in either UC Study 1 or in an open-label arm and achieved clinical response at Week 10 were re-randomized 1:1 and were treated with either ZEPOSIA 0.92 mg (n=230) or placebo (n=227) for 42 weeks (UC Study 2), for a total of 52 weeks of treatment. Corticosteroid tapering was required upon entering this study for patients who were receiving corticosteroids during the induction period.1

5-ASA=5-aminosalicylic acid; RBS=rectal bleeding subscore; SFS=stool frequency subscore; UC=ulcerative colitis.

Get Your Patients

Get Dedicated Support With
ZEPOSIA 360 SupportTM

To begin the process online,
click the button below to visit
Cover My Meds Icon

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.